A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1

To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.

Start Date22 Mar 2018

Sponsor / Collaborator

Eli Lilly & Co.

[+1]

NCT03382899 / TerminatedPhase 2

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)

To compare the efficacy of pegilodecakin in combination with pembrolizumab versus pembrolizumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.

Start Date19 Mar 2018

Sponsor / Collaborator

Eli Lilly & Co.

[+1]

NCT04194892 / CompletedPhase 1

An Open Label, Randomized, Single Dose, 2-Way Crossover Study to Evaluate the Pharmacokinetics of Pre-filled Syringe Versus Vial Formulations of AM0010 in Healthy Adult Subjects

The purpose of this study is to assess how fast pegilodecakin gets into the blood stream and how long it takes the body to remove it, when given as a solution formulation via a prefilled syringe (PFS) versus from a vial drawn into a conventional syringe. Information about side effects will be collected. The study is open to healthy participants. Total participant duration in trial is approximately 42 days.

Start Date19 Jan 2018

Sponsor / Collaborator

Eli Lilly & Co.

[+1]

100 Clinical Results associated with PEG-ilodecakin

100 Translational Medicine associated with PEG-ilodecakin

100 Patents (Medical) associated with PEG-ilodecakin

Literatures (Medical) associated with PEG-ilodecakin

26 Jul 2024·MEDICINE

Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review

Review

Author: Hou, Encun ; Chen, Sheng ; Gao, Hongjun ; Lan, Xuan ; Chen, Jibing ; Ma, Xiaohan ; Wei, Zengzhao

Immune checkpoint inhibitor (ICI) combinations, as well as ICIs combined with tyrosine kinase inhibitors, have considerable potential for renal cell carcinoma (RCC) treatment. Newer targeted medications, gut microbiome, nanomedicines, and cyclin-dependent kinase (CDK) inhibitors demonstrate significant potential in preventing side effects and resistance associated with RCC treatment. Most patients, including those demonstrating long-term treatment effects, eventually demonstrate cancer progression. Nevertheless, recent studies have further revealed RCC pathogenesis and many acquired drug resistance mechanisms, which together have led to the identification of promising therapeutic targets. In addition to having roles in metabolism, immunogenicity, and the immune response to tumors, CDK4 and CDK6 regulate the cell cycle. Targeting CDK4 and CDK6, either separately or in combination with already approved treatments, may improve therapeutic outcomes in patients with kidney cancer. Other novel drugs, including pegylated interleukin 10, colony-stimulating factor 1 receptor inhibitors, CD40 agonists, and C-X-C receptor 4 inhibitors affect the tumor microenvironment and cancer cell metabolism. Moreover, a triple ICI combination has been noted to be efficacious. In general, compared with sunitinib as a single-drug treatment, newer ICI combinations improve overall survival in patients with RCC. Future research on the prevention of adverse events and medication resistance related to newer therapies may aid in ensuring effective treatment outcomes among patients with RCC. This article aims to summarize innovative immunotherapy drug combinations for RCC treatment and the mechanisms of action, drug resistance, and treatment of adverse events associated with these combinations.

01 Apr 2024·Comparative medicine

Comparison of Two Different Alfaxalone Concentrations Combined with Midazolam to Anesthetize Cynomolgus Macaques (Macaca fascicularis) for Plethysmography

Article

Author: Santos, Kacee H ; White, Charles E ; Frick, Ondraya M ; Astleford, Summer M ; Marion, Brianna M ; Pasloske, Kirby S ; Edwards, Robert J ; Ghering, Jeanean M

Plethysmography is employed in nonhuman primates (NHPs) to calculate respiratory minute volume and determine the exposure time required to deliver an aerosol at the target dose. Anesthetic drugs can impact breathing parameters like steady-state minute volume (SSMV) central to aerosol dosing. Alfaxalone-midazolam mixtures (AM) provide superior parameters for plethysmography in cynomolgus macaques. An obstacle to the use of AM is the volume required to anesthetize via intramuscular injection. A more concentrated formulation of alfaxalone will reduce injection volumes and refine AM protocols. The purpose of this study was to compare AM using the Indexed 10-mg/mL (AM10) formulation compared with an investigational 40-mg/mL (AM40) formulation for IM administration in cynomolgus macaques undergoing plethysmography. We hypothesized that AM10 and AM40 would show no difference in quality of anesthesia (QA), duration of anesthesia, SSMV, accumulated minute volume (AMV), and side effects. We also hypothesized that female macaques would have a longer duration of anesthesia compared with males using both formulations. The study used 15 cynomolgus macaques comprised of 8 females and 7 males. NHPs were compared between 2 separate and randomized anesthetic events no less than one week apart. Each animal served as its own control and animals were randomized by random number generation. Anesthetized NHPs were placed in a sealed plethysmography chamber, and minute volume measurements were calculated every 10 s to determine SSMV. Once SSMV was achieved for 20 min, the trial ended. There were no statistically significant differences between AM10 and AM40 for duration of anesthesia, SSMV, AMV, side effects, or QA. AM40 had a significantly smaller injection volume. Females did not show a significantly longer median duration of anesthesia using either of the alfaxalone formulations. Overall, AM40 offers a more humane anesthetic than AM10 for plethysmography in cynomolgus macaques.

07 Feb 2024·ACS chemical neuroscience

Discovery of Quinolinone Hybrids as Dual Inhibitors of Acetylcholinesterase and Aβ Aggregation for Alzheimer’s Disease Therapy

Article

Author: Nafie, Mohamed S ; Khan, Ashma ; Nayeem, Shahid M ; Gabr, Moustafa T ; Raza, Md Kausar ; Arafa, Reem K ; Manzoor, Shoaib ; Hoda, Nasimul

The development of multitargeted therapeutics has evolved as a promising strategy to identify efficient therapeutics for neurological disorders. We report herein new quinolinone hybrids as dual inhibitors of acetylcholinesterase (AChE) and Aβ aggregation that function as multitargeted ligands for Alzheimer's disease. The quinoline hybrids (AM1-AM16) were screened for their ability to inhibit AChE, BACE1, amyloid fibrillation, α-syn aggregation, and tau aggregation. Among the tested compounds, AM5 and AM10 inhibited AChE activity by more than 80% at single-dose screening and possessed a remarkable ability to inhibit the fibrillation of Aβ₄₂ oligomers at 10 μM. In addition, dose-dependent screening of AM5 and AM10 was performed, giving half-maximal AChE inhibitory concentration (IC₅₀) values of 1.29 ± 0.13 and 1.72 ± 0.18 μM, respectively. In addition, AM5 and AM10 demonstrated concentration-dependent inhibitory profiles for the aggregation of Aβ₄₂ oligomers with estimated IC₅₀ values of 4.93 ± 0.8 and 1.42 ± 0.3 μM, respectively. Moreover, the neuroprotective properties of the lead compounds AM5 and AM10 were determined in SH-SY5Y cells incubated with Aβ oligomers. This work would enable future research efforts aiming at the structural optimization of AM5 and AM10 to develop potent dual inhibitors of AChE and amyloid aggregation. Furthermore, the in vivo assay confirmed the antioxidant activity of compounds AM5 and AM10 through increasing GSH, CAT, and SOD activities that are responsible for scavenging the ROS and restoring its normal level. Blood investigation illustrated the protective activity of the two compounds against lead-induced neurotoxicity through retaining hematological and liver enzymes near normal levels. Finally, immunohistochemistry investigation revealed the inhibitory activity of β-amyloid (Aβ) aggregation.

News (Medical) associated with PEG-ilodecakin

21 Feb 2024

·www.biospace.com

Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes

Martin Oft, M.D., assumes role of Chief Scientific Officer Greg Yedinak promoted to Chief Technical Officer MENLO PARK, Calif.--(BUSINESS WIRE)-- Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of Geoff Nosrati, Ph.D., as chief business officer. The company also announced additional changes in the executive leadership team, with Martin Oft, M.D., assuming the role of chief scientific officer and Greg Yedinak promoted to chief technical officer. “Geoff is an accomplished biotechnology executive with extensive knowledge in corporate strategy and business development,” said Debanjan Ray, chief executive officer of Synthekine. “His experience in portfolio strategy and transactions will be an asset to Synthekine as we continue to advance our wholly owned pipeline and progress our partnering activities.” Ray continued, “We’re also delighted to recognize Martin and Greg’s contributions to Synthekine with their new roles. Martin’s deep insights into cytokine biology and immunology were instrumental to shaping the development of STK-012, our first-in-class alpha/beta biased IL-2. Its unique mechanism expands the therapeutic index of IL-2, one of the most important immuno-oncology targets, providing improved efficacy while avoiding IL-2 related vascular toxicities. Greg’s broad expertise in the development and manufacturing of biologics and cell therapies has allowed us to advance both STK-012 and STK-009 + SYNCAR-001, our novel combination therapy of orthogonal IL-2 and CD19 CAR-T with potential to overcome limitations of current CD19 directed cell therapies in both hematological malignancies and autoimmune disease, into clinical development. Their contributions over the years have been invaluable to Synthekine’s rapid progress.” Dr. Nosrati is an expert in corporate strategy and business development with more than 20 years of experience in the biotechnology industry. He has worked across multiple modalities and therapeutic areas, with an emphasis on oncology, autoimmune and rare disease. Prior to joining Synthekine, Dr. Nosrati was chief business officer at Nutcracker Therapeutics. In his previous experience, he also served as chief business officer of ImmunoScape and held multiple senior executive roles at Aduro Biotech. In these positions, he worked closely with research, development, and commercial teams to strategically position the companies in the market and establish them as preferred partners for leading pharmaceutical and biotechnology organizations. Early in his career, Dr. Nosrati advised pharmaceutical and biotechnology clients at McKinsey & Co., with a focus on corporate strategy, finance, due diligence, and mergers and acquisitions. Dr. Nosrati holds a Ph.D. in Biochemistry and Molecular Biology from the University of California, Los Angeles and graduated with a B.S. in Chemistry from Duke University. Dr. Oft joined Synthekine at its formation in 2019 and previously served as the chief development officer. He is an expert in immune therapies, with in-depth experience in preclinical, translational, and clinical research and development of cytokine therapeutics for cancer and inflammatory disease. Prior to Synthekine, Dr. Oft co-founded ARMO Biosciences, where he oversaw pipeline development including pegilodecakin (pegylated IL-10) from early-target discovery through phase 3 clinical studies. He identified integrated immune-modulating strategies for the treatment of cancer, including the invigoration of tumor-specific T-cell immunity concomitant with inhibition of tumor-promoting inflammation. Prior to ARMO, Dr. Oft developed immune therapies for the treatment of cancer at DNAX Research in Palo Alto, now Merck Research Labs, and held positions at Onyx Pharmaceuticals, the UCSF Cancer Center and Boehringer Ingelheim. Dr. Oft earned his M.D. and medical license from the University of Erlangen, Germany. He performed his postdoctoral research at the Institute of Molecular Pathology in Vienna, Austria. Mr. Yedinak previously served as senior vice president of technical operations after joining the company in 2020. He has more than 30 years of experience in pharmaceutical, biologics, and medical device process development, manufacturing and operations. Prior to joining Synthekine, Greg was senior vice president of manufacturing and supply chain operations at PACT Pharma, where he was responsible for building the internal and CMO manufacturing operations for the PACT Pharma cell therapy programs. Prior to PACT Pharma, he held various executive and leadership positions at Versatis, Zosano, Nuvelo, Abgenix/Amgen and Genentech, where he was integral to the strategic production planning, process development, and production of numerous clinical and commercial products and devices. Greg earned a B.S. in biological sciences from the University of California-Irvine. About Synthekine Synthekine is harnessing the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatment paradigm of cancer and inflammatory disease. Using insights on cytokine structure and function, the company engineers therapeutics designed to unlock the full efficacy potential of cytokines while avoiding their associated toxicities. Synthekine is applying principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms to create a broad and deep pipeline of product candidates. These novel immunotherapies include modified cytokines, cytokine-enhanced cell therapies and surrogate cytokine agonists. For more information, visit , and follow us on Twitter @synthekine and LinkedIn. View source version on businesswire.com: Contacts Will Zasadny Inizio Evoke Comms 619-961-8848 will.zasadny@inizioevoke.com Source: Synthekine Inc. View this news release online at:

Executive ChangeImmunotherapyCell TherapyPhase 3

14 Nov 2022

·www.prnewswire.com

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

FN Media Group Presents USA News Group News Commentary VANCOUVER, British Colombia, Nov. 14, 2022 /PRNewswire/ -- USA News Group - English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his victory over pancreatic cancer, known as the world's deadliest common cancer. "The good news is that we are starting to fight back," said Idle after creating the Bright Side Fund to support research and help promote early detection. Despite US cancer death rates being down across all age groups, however mortality rates for pancreatic cancers have gone up, so there's much work to be done. Now there's developments in the fight against pancreatic cancer coming that are generating huge amounts of optimism from biotech groups such as O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Roche Holding AG (OTCQX: RHHBY), Eli Lilly and Company (NYSE: LLY), Bristol-Myers Squibb Company (NYSE: BMY), and BioNTech SE (NASDAQ: BNTX). One of the most promising new data sets in pancreatic cancer therapies is coming from pelareorep, developed by O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC). In the company's latest round of results from the ongoing multi-indication phase 1/2 GOBLET study, patients treated with a combination of pelareorep, with atezolizumab from Roche Holding AG (OTC: RHHBY), gemcitabine from Eli Lilly and Company (NYSE: LLY), and nab-paclitaxel from Celgene Corporation which is a subsidiary of Bristol-Myers Squibb Company (NYSE: BMY). Highlighting the impressive significance of the data, Oncolytics Biotech cites the Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine study published in 2013 by Dr. Von Hoff in the New England Journal of Medicine, which later that year led to the FDA approval of nab-paclitaxel for use in combination with gemcitabine to treat patients with metastatic pancreatic cancer. Now the pelareorep combination has produced data that to-date was almost unheard of, with nearly triple the objective response rate (ORR) with 69% vs 23-29% of the 2013 study. Perhaps even more significant, was the presence of a confirmed complete response (CR)—defined as the disappearance of all signs of cancer in response to treatment. Oncolytic Biotech's pelareorep trials produced a 7.7% CR (1 in 13) of test patients, compared to only 0.12% CR (1 in 861) from the 2013 group. "GOBLET's interim results indicate pelareorep may be the key to finally improving the standard-of-care for first-line treatment of pancreatic cancer, a clear need given that treatment options have not changed for many years despite their limited benefits," said Thomas C. Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics Biotech. "The robust efficacy signal in GOBLET markedly exceeded expectations based on historical results and is especially encouraging as most responding patients had their tumor regressions confirmed by subsequent evaluations. We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy." On top of the impressive ORR and CR, Oncolytics Biotech's pelareorep also achieved a clinical benefit rate (CBR) of 85% as of the SITC poster's data cutoff date of October 12, 2022. In comparison, a 1997 gemcitabine trial only delivered a 23.8% CBR. Back in June, Oncolytics Biotech announced it had achieved success criteria for efficacy in its pancreatic cancer cohort. Now as of their latest abstract's cutoff date, seven of ten evaluable patients in the cohort achieved a partial response. An additional two patients achieved stable disease for an ORR and clinical benefit rate of 70% and 90%, respectively. "The impressive results being presented at SITC, together with prior clinical data providing a strong mechanistic rationale for the apparent synergies being displayed by pelareorep, PD-L1 inhibition, and chemotherapy, support our pancreatic cancer program's advancement into a pivotal trial," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "We look forward to discussions with regulators to enable these efforts and align on the optimal design for a licensure-enabling study. In parallel, we continue to make strong progress with our breast cancer program; and are thrilled to be advancing a pipeline that includes two potentially compelling registration opportunities." With this latest data from GOBLET, it appears that the fastest route to a catalyst event will go through its combination with chemotherapy and checkpoint inhibition to treat pancreatic cancer. "These latest results indicate that pelareorep's immunotherapeutic effects may enhance the efficacy of checkpoint inhibitors in pancreatic cancer and increase tumor response rates," said Dirk Arnold M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial. "This promising finding suggests that pelareorep has the potential to dramatically improve the current therapeutic approach is an indication that is amongst the most difficult to treat." Another joint effort involving Roche Holding AG (OTC: RHHBY) that sparked early optimism this year was an mRNA therapy for pancreatic cancer developed with BioNTech SE (NASDAQ: BNTX). Back in June, BioNTech presented preliminary Phase I data of its BNT122, evaluating with Genentech (a Roche subsidiary) in pancreatic cancer. The Phase I trial is studying the mRNA-based individualized neoantigen specific immunotherapy (iNeST) autogene cevumeran (BNT122) in combination with atezolizumab, an anti-PD-L1 immune checkpoint inhibitor, and chemotherapy. The patients in the study have resected pancreatic ductal adenocarcinoma (PDAC). "With only under 5% of patients responding to current treatment options, PDAC is one of the highest unmet medical need cancers," said Dr. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer of BioNTech. "We are committed to take up this challenge by leveraging our long-standing research in cancer vaccinology and are trying to break new ground in the treatment of such hard-to-treat tumors." For Eli Lilly and Company (NYSE: LLY), the new developments with gemcitabine involved in pancreatic cancer therapies is a marked improvement upon the disappointment in 2019 that resulted after a $1.6 billion buyout of Armo Biosciences led to ending a Phase 3 study for pegilodecakin resulting from a poor showing in pancreatic cancer. Initially Bristol-Myers Squibb Company (NYSE: BMY) had more success with its massive $74-billion acquisition of Celgene in 2019, which led to obtaining the asset Abraxane—the brand name of nab-paclitaxel which is approved in breast, lung, and pancreatic cancer. However, Celgene was recently hit with an FDA warning letter because the BMS subsidiary didn't fix the problem of multiple media fill failures along the aseptic processing line at its biologics plant. French biotech giant Ipsen S.A. and its combination involving its asset Onivyde also demonstrated a statistically significant improvement in overall survival (OS) compared to the nab-paclitaxel+gemcitabine combination in patients with metastatic pancreatic ductal adenocarcinoma. The win for Ipsen comes roughly five years after the company paid potentially $1 billion for the pancreatic cancer drug, acquiring it from Merrimack Pharmaceuticals in 2017. Onivyde is also approved for patients with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection and is currently in a phase 3 confirmatory study in combination with Roche's Rituxan and Bristol Myers Squibb's Revlimid in patients with relapsed/refractory follicular lymphoma who have received at least one prior therapy. For more information please visit: Article Source: USA News Group [email protected] DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Media Contact Information: FN Media Group, LLC Media Contact e-mail: [email protected] U.S. Phone: +1(954)345-0611 SOURCE USA News Group

Clinical ResultImmunotherapyPhase 1Phase 3Drug Approval

03 Oct 2019

·www.bioportfolio.com

IL-10 Agonist Paired With Anti-PD-1 Shows Promise in Lung, Kidney Cancer

(MedPage Today) -- Added pegilodecakin to nivolumab or pembrolizumab yielded high activity in IVY study

100 Deals associated with PEG-ilodecakin

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15162

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Secondary malignant neoplasm of pancreas	Phase 3	US	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	AU	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	AT	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	BE	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	CA	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	FR	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	DE	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	IT	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	PL	Eli Lilly & Co.	01 Mar 2017
Secondary malignant neoplasm of pancreas	Phase 3	KR	Eli Lilly & Co.	01 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03382899 \| NCT03382912 (CYPRESS 2, Pubmed \| J Thorac Oncol)	Phase 2	metastatic non-small cell lung cancer Second line	-	Pegilodecakin + Pembrolizumab	ypzyvdrusp(vrldtinpga) = ubaburjbwy oidftvzaex (zdgegtenvd ) View more	Negative	01 Feb 2021
				Pembrolizumab	ypzyvdrusp(vrldtinpga) = vykyjypwtd oidftvzaex (zdgegtenvd ) View more
NCT03382899 (CYPRESS 1, CTgov)	Phase 2	metastatic non-small cell lung cancer	101	pembrolizumab+Pegilodecakin (Pegilodecakin + Pembrolizumab)	etyytscuio(vxhuelnopu) = gcswmcwosq pisqpjjohh (ucebtvwhic, hyznybjshh - reoleaqldk) View more	-	20 Jan 2021
				pembrolizumab (Pembrolizumab)	etyytscuio(vxhuelnopu) = gtypbytnlz pisqpjjohh (ucebtvwhic, ekaukvpsxi - hoioqzrswm) View more
NCT02923921 (Sequoia, CTgov)	Phase 3	Secondary malignant neoplasm of pancreas	567	folinic acid+Pegilodecakin+oxaliplatin+fluorouracil (Pegilodecakin + FOLFOX)	fcmfmiazfy(jpdmjtoxpd) = emargsgarz iybhkmuelf (sfpoxnkkqu, zdhbgrrxcu - tsuqsszwap) View more	-	19 Oct 2020
				folinic acid+oxaliplatin+fluorouracil (FOLFOX)	fcmfmiazfy(jpdmjtoxpd) = feedukvlyg iybhkmuelf (sfpoxnkkqu, zmxldjzjmk - avbofsqocq) View more
NCT03382912 (CYPRESS 2, CTgov)	Phase 2	metastatic non-small cell lung cancer	52	Nivolumab	xrmizzpobk(pjtxlzmggc) = saipqyetpq pvsqbiahac (mfqrppvjjs, svcamwlabw - cnkoinszip) View more	-	11 Sep 2020
NCT03382912 (CYPRESS 2, ASCO2020) Manual	Phase 2	Non-Small Cell Lung Cancer PD-L1 Low Expression \| PD-L1 No Expression	52	nivolumab+pegilodecakin	vgumimfdca(wrfzaxdfvm) = jzlyjsvpsl poicdfhlfo (bwrzfmqoel ) View more	Negative	29 May 2020
				nivolumab	vgumimfdca(wrfzaxdfvm) = bcptiuibnu poicdfhlfo (bwrzfmqoel ) View more
NCT03382899 (CYPRESS 1, ASCO2020) Manual	Phase 2	PD-L1 positive Non-Small Cell Lung Cancer First line PD-L1 High Expression	101	Pegilodecakin+Pembrolizumab	hovadrwfef(utmmxjbwui) = xifftgelfx orelvvihen (obzsjrdecd ) View more	Negative	29 May 2020
				Pembrolizumab	hovadrwfef(utmmxjbwui) = xysijpejpr orelvvihen (obzsjrdecd ) View more
NCT02923921 (SEQUOIA, ASCO_GI2020) Manual	Phase 3	Pancreatic Ductal Adenocarcinoma Second line	567	Leucovorin+oxaliplatin+5-FU+Pegilodecakin	nbjrilzqld(rhedjechjt) = avggqgxckf qeaxagdwto (mqncygdtmn ) View more	Negative	24 Jan 2020
				Leucovorin+oxaliplatin+5-FU	nbjrilzqld(rhedjechjt) = ybbgbkgtxx qeaxagdwto (mqncygdtmn ) View more
NCT02009449 (IVY, Pubmed) Manual	Phase 1	Solid tumor	111	pembrolizumab+Pegilodecakin	qdesczuszt(qhrufjdcfa) = kbsrhqgjxv qiqchpfztn (cdoqgzgush )	Positive	01 Nov 2019
				pegilodecakin+nivolumab	qdesczuszt(qhrufjdcfa) = hxwqgrtpwm qiqchpfztn (cdoqgzgush )
SITC2018	Not Applicable	Neoplasms	-	Pegilodecakin	kjsbxmwdkd(nuhyqkskvm) = Pegilodecakin treatment induced the hallmarks of CD8+ T-cell immunity in cancer patients, including the systemic elevation of IFNg and GranzymeB levels, expansion and activation of CD8+ TILs, invigoration and expansion of PD-1+/Lag-3+ CD8+ T-cell sub-set and the de-novo expansion of T-cell clones yenqciyckm (nokpthedqy ) View more	Positive	06 Nov 2018
WCLC2018	Not Applicable	Non-Small Cell Lung Cancer	34	Pegilodecakin + Pembrolizumab	vykwgbxgse(dbptdqqbbd) = oukuflklvu zdvrepcnor (iqgbosliad ) View more	-	24 Sep 2018
				Pegilodecakin + Nivolumab	zyeorphgzg(jgqddsylrl) = dvafhogtla zyeyxrngiz (zcfessvpjf )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis